Back to Search
Start Over
Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy against Metastatic Tumors
- Source :
- Advanced Healthcare Materials. 11:2101496
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- The major obstacles of anti-PD therapy in metastatic tumors are limited drug delivery in primary tumors and metastatic foci, and the lack of tumor-infiltrating lymphocytes (TILs). Here, the authors constructed a novel cellular membrane nanovesicles platform (M/IR NPs) based on homologous targeting and near-infrared (NIR) responsive release strategy to potentiate PD-1/PD-L1 blockade therapy against metastatic tumors. In tumor-bearing mice, biomimetic M/IR NPs targeted both primary tumors and their lung metastases. Upon laser irradiation, M/IR NPs reduced cancer-associated fibroblasts (CAFs) in tumor microenvironment, thus increasing the penetration of TILs. When shed from homologous tumor cell membranes, positively charged nanoparticles (IR NPs) core can capture released tumor-associated antigens, thereby enhancing the antigen-presenting ability of DCs to activate cytotoxic T lymphocytes. When the photothermal conversion temperature under NIR-laser is higher than 42 °C, M/IR NPs initiated the rupture of cell membranes and the responsive release of PD-1/PD-L1 inhibitor BMS, which significantly attenuated tumor-associated immunosuppression and synergistically induced T cellular immunity to inhibit the tumor growth and metastasis. Overall, biomimetic M/IR NPs can improve the targeting and therapeutic efficacy of anti-PD therapy in primary tumors and metastases, opening up a new avenue for the diagnosis and treatment of metastatic tumors in the future.
Details
- ISSN :
- 21922659 and 21922640
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Advanced Healthcare Materials
- Accession number :
- edsair.doi.dedup.....18d43dca62a2604c07cc30011fe99913